2022-05-19

MLO Online: COVID-19’s impact on testing practices for STIs

James Walker

The decrease in STI testing seen during the first few months of the pandemic resulted in low reporting of disease. As patients get back to doctors’ offices to catch-up on delayed screenings, STI testing demand is now on the rise. Laboratories are faced with higher volumes of tests to process with fewer staff members and shortages of laboratory consumables.

James Walker, Global Business Leader of Molecular Diagnostics & Women’s Health and Cancer at BD, shares his insights into the challenges faced by labs and the steps labs can take to diagnose patients with greater accuracy and efficiency.

Latest resources

Discover our latest articles, webinars, press releases and updates in women's health.

ReachMD: A review of risk in cervical cancer: An analysis of the ASCCP guidelines & NCI risk matrix
Cervical Cancer | Webinars & Videos
ReachMD: A review of risk in cervical cancer: An analysis of the ASCCP guidelines & NCI risk matrix
Specimen collection for the BD CTGCTV2 assay
Specimen Collection for the BD CTGCTV2 Assay
Cervical Cancer Screening: The Current State of Testing
Cervical Cancer | Articles & Publications
Cervical Cancer Screening: The Current State of Testing